Skip to main content
SpringerLink
Log in

Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in advanced breast cancer

A Phase II trial of the Southwest Oncology Group

  • Clinical Trials
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The Southwest Oncology Group has evaluated methyl-GAG on a weekly schedule among patients with metastatic breast cancer. Among 72 fully and partial evaluable patients, one complete and four partial responses were seen. Toxicity was similar to other trials with this compound except for thrombocytopenia which was more frequent and severe and probably related to tumor infiltrating marrow. In addition, one patient experienced recall dermatitis following methyl-GAG. This toxicity has not been previously reported with this compound. Methyl-GAG has minimal activity at this dose and schedule among heavily pretreated patients with breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Knight WA III, Livingston RB, Fabian C, Constanzi J: Phase I–II trial of methyl-GAG: A Southwest Oncology Group pilot study. Cancer Treat Rep 63:1933–1937, 1979

    Google Scholar 

  2. Warrell RP, Burcheval JH: Methyl-glyoxal bis guanyl hydrazone (methyl-GAG): current status and future prospects. J Clin Oncol 1:52–65, 1983

    Google Scholar 

  3. Yap HY, Blumenschein GR, Schell FC, Bodey GP: Phase II evaluation of Methyl-GAG in patients with refractory metastatic breast cancer. Cancer Treat Rep 65:465–467, 1981

    Google Scholar 

  4. Knight WA, Von Hoff DD, Neidhart JA, Tranum BL, Fabian C, Jones SE: Dihydroxyanthracenedione in advanced breast cancer. A Phase II trial of the Southwest Oncology Group. Invest N Drugs 1:151–154, 1983

    Google Scholar 

  5. Yap HY, Blumenschein GR, Schell FC, Buzdar AU, Valdivieso M, Bodey GP: Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Int Med 95:694–697, 1981

    Google Scholar 

  6. Neidhart JA, Roach RW: A randomized study of mitoxantrone and adriamycin in breast cancer patients failing primary therapy. Proc Am Soc Clin Onco 1:86, 1982 (Abstract)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas Health Science Center, San Antonio, TX

    William A. Knight III

  2. Henry Ford Hospital, Detroit, MI

    Robert M. O'Bryan

  3. Wayne State University, Detroit, MI

    Bohumil Samal

  4. University of Texas Medical Branch at Galveston, Galveston, TX

    John J. Costanzi

Authors
  1. William A. Knight III
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert M. O'Bryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bohumil Samal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John J. Costanzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Address for reprints: Southwest Oncology Group (7921), 4450 Medical Drive, San Antonio, TX 78229, U.S.A.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knight, W.A., O'Bryan, R.M., Samal, B. et al. Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in advanced breast cancer. Invest New Drugs 2, 71–73 (1984). https://doi.org/10.1007/BF00173789

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00173789

Key words

Search

Navigation